Generics Bulletin is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
With over 20 years of experience of reporting on the global pharmaceutical industry, Aidan focuses in his role as editor of Generics bulletin particularly on commercial, regulatory and legal issues affecting the generic, biosimilar, value-added and OTC medicines industries. This includes in-depth analyses of corporate strategy, legislative changes, legal precedents and product perspectives. He regularly interviews leading industry executives and moderates prestigious events. Aidan also oversees the Global Generics & Biosimilars Awards. Aidan speaks fluent German and has a particular affection for maps.
Evidence put forward by manufacturers to support fixed-dose combinations must be considered by an advisory committee to India’s government, the Delhi High Court has ordered in a verdict favouring Wockhardt.
By the middle of this year, biosimilars developer Alvotech plans to have strategic alliances in place with a handful of regional partners to commercialize its pipeline of seven biosimilar monoclonal antibodies.